The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
Completed
Phase 1
NCT ID: NCT02309177
ORG ID: ABI-007-ST-001
Breast Neoplasms
Pancreatic Neoplasms
| Drug | Synonyms | Arms |
|---|---|---|
| nab-Paclitaxel | Abraxane | nab-Paclitaxel and Nivolumab in Pancreatic Cancer, nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer, nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC, nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC, nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC, nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC |
| Nivolumab | BMS-936558 or MDX1106 | nab-Paclitaxel and Nivolumab in Pancreatic Cancer, nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer, nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC, nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC, nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC, nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC |
| Gemcitabine | Gemzar | nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer |
| Carboplatin | Paraplatin | nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC, nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC |
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens
administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small
Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).
This will be a phase 1, open-label, multicenter, safety study of nab-paclitaxel based
chemotherapy regimens administered prior to and/or in combination with nivolumab in
Pancreatic Cancer, NSCLC and mBC. This is a six arm study assessing two treatment arms per
tumor-type/indication:
- Adenocarcinoma of the pancreas with 1 prior systemic chemotherapy (Arm A, Part 1 only);
and subsequently no prior chemotherapy, surgery or radiation therapy for locally
advanced or metastatic disease (Arm A, Part 2 and Arm B):
- Panc Ca Arm A: nab-paclitaxel with nivolumab starting at Cycle 1.
- Panc Ca Arm B: nab-paclitaxel/gemcitabine with nivolumab starting at Cycle 1.
- Stage IIIB or IV NSCLC with no prior chemotherapy for metastatic disease and who are
not candidates for curative surgery or radiation:
- NSCLC Arm C: nab-paclitaxel/carboplatin x 4 cycles with nivolumab starting Cycle
1 and continuing as monotherapy starting at Cycle 5.
- NSCLC Arm D: nab-paclitaxel/carboplatin x 4 cycles with nivolumab starting Cycle
3 and continuing as monotherapy starting at Cycle 5
- HER2-negative recurrent metastatic breast cancer after one prior regimen for mBC,
including an anthracycline unless clinically contraindicated:
- mBC Arm E: weekly nab-paclitaxel with nivolumab starting at Cycle 3.
- mBC Arm F: q3weekly nab-paclitaxel with nivolumab starting at Cycle 3.
Enrollment in each treatment arm will be conducted in two sequential parts to
allow for the evaluation of the DLT in Part 1 prior to expanding the treatment arm
in Part 2.
Part 1:
Part 1 will assess the Dose Limiting Toxicity (DLT) of the nivolumab dose in combination
with nab-paclitaxel regimens in each treatment arm.
Subjects who meet the entry criteria will be assigned to the respective treatment arm based
on tumor type and indication as outlined above. Panc Ca Arms A and B, as well as NSCLC Arms
C and D, will enroll sequentially in Part 1. The safety of nivolumab in combination with
nabpaclitaxel, without gemcitabine, will first be assessed in Arm A in subjects with one
prior systemic chemotherapy regimen for locally advanced or metastatic disease. Panc Ca Arm
B may begin enrolling subjects in Part 1, if Panc Ca Arm A is deemed safe, based on DLT
criteria. Similarly, NSCLC Arm D will begin to enroll in Part 1 after NSCLC Arm C is deemed
safe to expand in Part 2. However, Arm D may be initiated, even if Arm C is not to proceed
for Part 2, if the totality of data from Arm C and emerging data from this and other studies
in NSCLC with nivolumab in combination with platinum chemotherapy doublets support the
decision. Unlike the Panc Ca and NSCLC arms, the two mBC arms (Arms E and F) will be
initiated simultaneously. Subjects will be assigned randomly between treatment arms of a
tumor type/indication whenever both treatment arms are enrolling. An IRT system will be used
to ensure the central random allocation of subjects.
Part 2:
Treatment arms deemed safe within each tumor-type/indication may be expanded using the RP2D
with an additional approximately 14 subjects (to attain a total of 20 nivolumab-treated
subjects) to further assess safety and tolerability, as well as explore anti-tumor activity
of the proposed regimens. Since the primary population for the pancreas arms is in subjects
with no prior chemotherapy, surgery or radiation therapy, enrollment in Part 2 for Panc Ca
Arm A will continue until 20 such subjects have been treated with at least one dose of
nivolumab. Additionally, in Parts 1 and 2 overall, each mBC Arm (E and F) will enroll a
minimum of 9 subjects with triple- negative breast cancer (TNBC), treated at the RP2D.
For both Part 1 and 2, subjects may continue to receive their assigned treatment regimen
until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined progression or until
unacceptable toxicity. However, the chemotherapy doublet will only be given for 4 cycles in
the NSCLC arms; thereafter, nivolumab will be given as monotherapy.
| Name | Type | Description | Interventions |
|---|---|---|---|
| nab-Paclitaxel and Nivolumab in Pancreatic Cancer | Experimental | nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle. | nab-Paclitaxel, Nivolumab |
| nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer | Experimental | nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle. | nab-Paclitaxel, Nivolumab, Gemcitabine |
| nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC | Experimental | nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1. | nab-Paclitaxel, Nivolumab, Carboplatin |
| nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC | Experimental | nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3. | nab-Paclitaxel, Nivolumab, Carboplatin |
| nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC | Experimental | nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3. | nab-Paclitaxel, Nivolumab |
| nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC | Experimental | nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3. | nab-Paclitaxel, Nivolumab |
Inclusion Criteria:
1. Subject is male or female, 18 years old at the time of signing the informed consent
form (ICF).
2. Subject has a confirmed diagnosis of advanced unresectable solid tumors in the target
subject population within the parameters mentioned:
1. Pancreatic Cancer
- Subject has a definitive histologically or cytologically confirmed locally
advanced or metastatic adenocarcinoma of the pancreas. Subjects with islet
cell neoplasms are excluded.
- nab-Paclitaxel and Nivolumab: Subjects must have received 1 prior systemic
chemotherapy regimen for locally advanced or metastatic disease.
- nab-Paclitaxel + Nivolumab and nab-paclitaxel , Gemcitabine and Nivolumab
: Subjects must have received no previous radiotherapy, surgery,
chemotherapy or investigational therapy for the treatment of locally
advanced or metastatic disease. Subjects having received cytotoxic doses of
gemcitabine or any other chemotherapy in the adjuvant setting are not
eligible for inclusion. Prior treatment with 5-FU or gemcitabine
administered as a radiation sensitizer in the adjuvant setting is allowed,
but 6 months must have elapsed since completion of the last dose and no
lingering toxicities may be present. Initial diagnosis of metastatic
disease must have occurred 6 weeks prior to randomization in the study.
2. Non-small Cell Lung Cancer (NSCLC):
- Subject has definitive histologically or cytologically confirmed Stage IIIB
or IV NSCLC.
- Subjects must have received no previous chemotherapy or investigational
therapy for the treatment of metastatic disease. Adjuvant chemotherapy is
permitted providing cytotoxic chemotherapy was completed > 12 months prior
to randomization, without disease recurrence or progression during those 12
months.
3. Recurrent Metastatic Breast Cancer: Human Epidermal Growth Factor Receptor 2 -
negative (HER2(-)) recurrent metastatic Breast Cancer:
- Subject has a definitive histologically or cytologically confirmed
diagnosis of HER2(-) metastatic breast cancer.
- Subject has received one prior cytotoxic chemotherapy regimen for
metastatic disease, including an anthracycline unless clinically
contraindicated. (Clinically contraindicated is defined as unless: [a.]
anthracycline treatment was not indicated or was not the best treatment
option for the subject in the opinion of the treating physician; and [b.]
anthracycline treatment remains not indicated or, in the opinion of the
treating physician, is not the best treatment option for the subject's
metastatic disease.)
- If subject has received solvent-based paclitaxel (TAXOL) or docetaxel as
adjuvant chemotherapy, subject must not have relapsed with breast cancer
within 12 months of completing said therapy.
- Suitable candidate for single agent nab-paclitaxel as assessed by the
investigator. Subject has measurable disease according to RECIST 1.1.
3. Archival formalin-fixed, paraffin-embedded tumor sample collected within 90 days
prior to subject consent available or subject has biopsiable metastatic lesion and is
willing to undergo biopsy .
4. Subject has no other malignancy within 5 years, except non-melanoma skin cancer,
cervical intraepithelial neoplasia, or in-situ cervical cancer.
5. Subject has the following laboratory values at screening:
- WBCs 2000/uL,
- Absolute neutrophil count (ANC) 1.5 x 109/L,
- Hemoglobin (Hgb) 90 g/L,
- Platelets (plt) 100 x 109/L,
- Potassium within normal range, or correctable with supplements,
- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x
Upper Limit of Normal (ULN) or 3.0 x ULN if liver tumor is present,
- Serum total bilirubin 1.5 x ULN (except in subjects with Gilbert's who may
have serum bilirubin < 3.0 x ULN),
- Serum creatinine 1.5 x ULN, or 24-hr clearance 60 mL/min,
- Normal coagulation [prothrombin time and partial thromboplastin time within
normal limits (15%)].
6. Subject has resting baseline oxygen saturation by pulse oximetry of 92% at rest.
7. Females of child-bearing potential (defined as a sexually mature woman who: 1) has
not undergone a hysterectomy (the surgical removal of the uterus) or bilateral
oophorectomy (the surgical removal of both ovaries) or, 2) has not been naturally
postmenopausal for at least 24 consecutive months (ie, has had menses at any time
during the preceding 24 consecutive months) must:
1. Agree in writing to use, and be able to comply with, highly effective
contraception (failure rate less than 1% per year) based on Appendix B without
interruption while on study treatment and for 23 weeks after discontinuation;
and
2. Have a negative serum pregnancy test result (minimum sensitivity 25 IU/L or
equivalent units of -hCG (Beta Subunit of Human Chorionic Gonadotropin)) at
screening and 24 hours prior to the start of any IP and agree to ongoing
pregnancy testing during the course of the study, and after the end of study
therapy.
3. Women must not be breastfeeding. (Females should not be breastfeeding while
receiving nivolumab and up to 18 weeks from the last dose of nivolumab).
8. Male subjects agree in writing to use a condom during sexual contact with a pregnant
female or a female of childbearing potential while participating in the study, during
dose interruptions and for 31 weeks following IP discontinuation, even if he has
undergone a successful vasectomy.
9. Subject or his/her legally authorized representative or guardian understands and
voluntarily signs an informed consent document prior to any study related
assessments/procedures are conducted (except as noted in Section 6).
10. Subject is able to adhere to the study visit schedule and other protocol
requirements.
Exclusion Criteria:
1. Subject has a history of allergy or hypersensitivity to any study drugs or their
excipients.
2. Subject has symptomatic brain metastases, spinal cord compression, or intractable
back pain due to compression of destructive mass.
3. Subject has active, known or suspected autoimmune disease, including systemic lupus
erythematodes, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa or
auto-immune hepatitis. Subjects with Type I diabetes mellitus, hypothyroidism only
requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or
alopecia) not requiring systemic treatment, or conditions not expected to recur in
the absence of an external trigger are permitted to enroll.
4. Subject is currently receiving or requires treatment with immunosuppressive agents or
immunosuppressive doses of systemic corticosteroids (unless used to treat
drug-related adverse events).Topical, ocular, intra-articular, intranasal,
inhalational corticosteroids (with minimal systemic absorption), and some uses of
systemic corticosteroids are permitted as per Section 9.1.
5. Subject has any peripheral neuropathy NCI CTCAE (National Cancer Institute Common
Terminology Criteria for Adverse Events ) Grade 2 at randomization/enrollment.
6. Subject has a history of interstitial lung disease, history of slowly progressive
dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary
fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies. Any lung
disease that may interfere with the detection or management of suspected drug-related
pulmonary toxicity.
7. Subject has a high cardiovascular risk, including, but not limited to, recent
coronary stenting or myocardial infarction in the past year.
8. Subject has unstable angina, a significant cardiac arrhythmia, or New York Heart
Association Class 3 or 4 congestive heart failure.
9. Subject has a history of peripheral artery disease (eg, claudication, Leo Buerger's
disease).
10. Subject has had major surgery, other than diagnostic surgery, within 4 weeks prior to
treatment in study.
11. Subject has known acute or chronic pancreatitis.
12. Subject has persistent diarrhea, malabsorption, or known sub-acute bowel obstruction
NCI CTCAE Grade 2, despite medical management.
13. Subject has active, uncontrolled bacterial, viral, or fungal infection(s) requiring
systemic therapy.
14. Subject has any history of testing positive for Human Immunodeficiency Virus (HIV) or
known acquired immunodeficiency disorder (AIDS).
15. Subject has historical or active infection with hepatitis B, or hepatitis C.
16. Subject is pregnant or breast-feeding.
17. Subject is currently enrolled in any other clinical protocol or investigational trial
that involves administration of experimental therapy and/or therapeutic devices, or
investigational drug.
18. Subject is currently using or use within 6 months of illicit drugs.
19. Subject has any significant medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from participating in the study.
20. Subject has any condition, including the presence of laboratory abnormalities, which
places the subject at unacceptable risk if he/she were to participate in the study.
21. Subject has any condition that confounds the ability to interpret data from the
study.
Minimum Eligible Age: 18 Years
Maximum Eligible Age: N/A
Eligible Gender: Both
Evaluate Dose Limiting Toxicity (DLT) of each combination regimen
Evaluate the safety of the nab-paclitaxel/nivolumab combination regimens
Grade 3 or 4 TEAE
Treatment Emergent Adverse Events
Progression-free survival
Overall Survival
Disease Control Rate
Overall Response Rate
Duration of Response
Pancreatic Cancer
Breast Cancer
Metastatic Breast Cancer
nab-Paclitaxel
Gemcitabine
Carboplatin
Non-Small Cell Lung Cancer
Lung Cancer
mBC
NSCLC
Triple-negative Breast Cancer
Hormone Receptor Positive
ER+
PR+
TNBC
Nivolumab
PD-1
Check-point Inhibitor/s
Immune Check-point Inhibitor/s
Anti-PD-1
BMS-936558
